ORINF News and Press, Orion Corp New B Shs From 01/08/24

2024-01-08 04:59:59 ET More on Orion: Historical earnings data for Orion Oyj Dividend scorecard for Orion Oyj Financial information for Orion Oyj For further details see: Orion collaborates with Glykos to develop next-generation ADCs

ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs Orion Corporation and Glykos Finland Oy announced today that they have entered into a research collaborat...

ORION CORPORATION PRESS RELEASE 05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer OMAHA1 and OMAHA2a are the first Phase 3 trials to be initiated for...

ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208 The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5...

Orion Research Foundation grants EUR 1,112,000 for research in 2024 Press release 15 November, 2023 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024. Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 ...

ORION CORPORATION PRESS RELEASE 31 July 2023 at 14.00 EEST European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder The European Commission has granted marketi...

ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate cancer Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have...

ORION CORPORATION PRESS RELEASE 20 March 2023 at 09:00 EET Darolutamide approved for additional prostate cancer indication in China Darolutamide now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additiona...

ORION CORPORATION PRESS RELEASE 1 March 2023 at 13:00 EET Darolutamide receives EU approval for additional indication in prostate cancer European Commission granted approval of darolutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) A...

ORION CORPORATION PRESS RELEASE 27 February 2023 at 9:00 EET D arolutamide receives approval for additional prostate cancer indication in Japan Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer ...